233 related articles for article (PubMed ID: 30898575)
1. Construction of replication-competent oncolytic retroviral vectors expressing R peptide-truncated 10A1 envelope glycoprotein.
Lee ES; Jin SY; Kang BK; Jung YT
J Virol Methods; 2019 Jun; 268():32-36. PubMed ID: 30898575
[TBL] [Abstract][Full Text] [Related]
2. Construction of a replication-competent retroviral vector for expression of the VSV-G envelope glycoprotein for cancer gene therapy.
Jin SY; Jung YT
Arch Virol; 2020 May; 165(5):1089-1097. PubMed ID: 32146506
[TBL] [Abstract][Full Text] [Related]
3. A Replication-Competent Retroviral Vector Expressing the HERV-W Envelope Glycoprotein is a Potential Tool for Cancer Gene Therapy.
Kang BK; Jung YT
J Microbiol Biotechnol; 2024 Feb; 34(2):280-288. PubMed ID: 38247210
[TBL] [Abstract][Full Text] [Related]
4. Lentiviral vectors pseudotyped with envelope glycoproteins derived from gibbon ape leukemia virus and murine leukemia virus 10A1.
Stitz J; Buchholz CJ; Engelstädter M; Uckert W; Bloemer U; Schmitt I; Cichutek K
Virology; 2000 Jul; 273(1):16-20. PubMed ID: 10891403
[TBL] [Abstract][Full Text] [Related]
5. MLV-10A1 retrovirus pseudotype efficiently transduces primary human CD4+ T lymphocytes.
Gladow M; Becker C; Blankenstein T; Uckert W
J Gene Med; 2000; 2(6):409-15. PubMed ID: 11199261
[TBL] [Abstract][Full Text] [Related]
6. Characterization of R peptide of murine leukemia virus envelope glycoproteins in syncytium formation and entry.
Kubo Y; Tominaga C; Yoshii H; Kamiyama H; Mitani C; Amanuma H; Yamamoto N
Arch Virol; 2007; 152(12):2169-82. PubMed ID: 17851730
[TBL] [Abstract][Full Text] [Related]
7. Antibody-mediated targeting of replication-competent retroviral vectors.
Tai CK; Logg CR; Park JM; Anderson WF; Press MF; Kasahara N
Hum Gene Ther; 2003 May; 14(8):789-802. PubMed ID: 12804141
[TBL] [Abstract][Full Text] [Related]
8. Production of a replicating retroviral vector expressing Reovirus fast protein for cancer gene therapy.
Jeon YH; Jung YT
J Virol Methods; 2022 Jan; 299():114332. PubMed ID: 34655690
[TBL] [Abstract][Full Text] [Related]
9. Highly efficient gene delivery for bladder cancers by intravesically administered replication-competent retroviral vectors.
Kikuchi E; Menendez S; Ozu C; Ohori M; Cordon-Cardo C; Logg CR; Kasahara N; Bochner BH
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4511-8. PubMed ID: 17671137
[TBL] [Abstract][Full Text] [Related]
10. Replacement of the murine leukemia virus (MLV) envelope gene with a truncated HIV envelope gene in MLV generates a virus with impaired replication capacity.
Nack U; Schnierle BS
Virology; 2003 Oct; 315(1):209-16. PubMed ID: 14592772
[TBL] [Abstract][Full Text] [Related]
11. Characterization of retroviral and lentiviral vectors pseudotyped with xenotropic murine leukemia virus-related virus envelope glycoprotein.
Sakuma T; De Ravin SS; Tonne JM; Thatava T; Ohmine S; Takeuchi Y; Malech HL; Ikeda Y
Hum Gene Ther; 2010 Dec; 21(12):1665-73. PubMed ID: 20507233
[TBL] [Abstract][Full Text] [Related]
12. Efficient Pseudotyping of Different Retroviral Vectors Using a Novel, Codon-Optimized Gene for Chimeric GALV Envelope.
Mirow M; Schwarze LI; Fehse B; Riecken K
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452336
[TBL] [Abstract][Full Text] [Related]
13. Mutational library analysis of selected amino acids in the receptor binding domain of envelope of Akv murine leukemia virus by conditionally replication competent bicistronic vectors.
Bahrami S; Jespersen T; Pedersen FS; Duch M
Gene; 2003 Oct; 315():51-61. PubMed ID: 14557064
[TBL] [Abstract][Full Text] [Related]
14. Increased gene transfer into human hematopoietic progenitor cells by extended in vitro exposure to a pseudotyped retroviral vector.
von Kalle C; Kiem HP; Goehle S; Darovsky B; Heimfeld S; Torok-Storb B; Storb R; Schuening FG
Blood; 1994 Nov; 84(9):2890-7. PubMed ID: 7524756
[TBL] [Abstract][Full Text] [Related]
15. VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment.
Qiao J; Moreno J; Sanchez-Perez L; Kottke T; Thompson J; Caruso M; Diaz RM; Vile R
Gene Ther; 2006 Oct; 13(20):1457-70. PubMed ID: 16724095
[TBL] [Abstract][Full Text] [Related]
16. Transduction efficiency of MLV but not of HIV-1 vectors is pseudotype dependent on human primary T lymphocytes.
Mühlebach MD; Schmitt I; Steidl S; Stitz J; Schweizer M; Blankenstein T; Cichutek K; Uckert W
J Mol Med (Berl); 2003 Dec; 81(12):801-10. PubMed ID: 14576928
[TBL] [Abstract][Full Text] [Related]
17. Efficient Prodrug Activator Gene Therapy by Retroviral Replicating Vectors Prolongs Survival in an Immune-Competent Intracerebral Glioma Model.
Chen SH; Sun JM; Chen BM; Lin SC; Chang HF; Collins S; Chang D; Wu SF; Lu YC; Wang W; Chen TC; Kasahara N; Wang HE; Tai CK
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32093290
[TBL] [Abstract][Full Text] [Related]
18. Characterization of recombination events leading to the production of an ecotropic replication-competent retrovirus in a GP+envAM12-derived producer cell line.
Garrett E; Miller AR; Goldman JM; Apperley JF; Melo JV
Virology; 2000 Jan; 266(1):170-9. PubMed ID: 10612671
[TBL] [Abstract][Full Text] [Related]
19. Basis for receptor specificity of nonecotropic murine leukemia virus surface glycoprotein gp70SU.
Ott D; Rein A
J Virol; 1992 Aug; 66(8):4632-8. PubMed ID: 1321266
[TBL] [Abstract][Full Text] [Related]
20. The effects of human serum and cerebrospinal fluid on retroviral vectors and packaging cell lines.
Russell DW; Berger MS; Miller AD
Hum Gene Ther; 1995 May; 6(5):635-41. PubMed ID: 7578400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
